Generic pharma companies unlikely to be impacted by Trump's order to cut Rx drug prices: Report

A report suggests Indian generic drug companies may not be affected by US President Donald Trump's order. The order aims to lower US prescription drug prices. It will match them to those of other developed nations. The 'Most-Favoured-Nation' price model will be introduced. This model will cover Medicare and Medicaid. The order may face legal challenges.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5yvpVTa
via IFTTT